Asthma: A Comprehensive Review of Pathophysiology, Underfunding, Disparities, and Future Research Directions

Asthma: A Comprehensive Review of Pathophysiology, Underfunding, Disparities, and Future Research Directions

Abstract

Asthma, a chronic inflammatory disorder of the airways, represents a significant global health burden, particularly affecting children. Despite its high prevalence and substantial impact on individuals and healthcare systems, asthma research remains comparatively underfunded, hindering advancements in understanding its complex pathophysiology and development of novel therapeutic strategies. This review provides a comprehensive overview of asthma, encompassing its underlying mechanisms, the reasons for research underfunding, the impact of asthma on pediatric and adult populations, current treatment approaches, and existing disparities in care and outcomes. We critically analyze the limitations of current therapies and highlight potential avenues for future research, including precision medicine approaches, novel therapeutic targets, and strategies to address health inequities. We examine the interplay between genetic predisposition, environmental exposures, and immunological responses in asthma pathogenesis. The persistent underfunding of asthma research is examined within the context of broader research funding allocation and advocate for increased investment to accelerate progress toward more effective and equitable asthma management.

1. Introduction

Asthma, derived from the Greek word meaning “panting,” is characterized by chronic airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction. This complex interplay of factors leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning [1]. While asthma can develop at any age, it is predominantly a disease of childhood, affecting millions of children worldwide. The global prevalence of asthma varies considerably depending on geographical location, socioeconomic status, and environmental factors [2]. In many developed nations, asthma prevalence rates are plateauing, although a decrease in prevalence may be observed in some countries, however the burden of disease is still substantial [3]. Conversely, in developing countries, asthma prevalence is increasing, likely due to urbanization, industrialization, and changing lifestyles [4].

Asthma poses a significant economic burden, resulting from healthcare utilization, medication costs, lost productivity, and school absenteeism. Children with asthma often experience impaired quality of life, impacting their physical activity, sleep, and social participation [5]. In severe cases, asthma can lead to life-threatening exacerbations requiring hospitalization and intensive care. The clinical manifestations of asthma are diverse, ranging from mild intermittent symptoms to severe persistent disease. This heterogeneity underscores the need for personalized approaches to asthma management, taking into account individual patient characteristics and disease severity.

Despite the high prevalence and impact of asthma, research funding for asthma lags behind other chronic diseases with comparable or even lower prevalence rates. This disparity in funding hinders progress in understanding the complex pathophysiology of asthma, identifying novel therapeutic targets, and developing more effective and personalized treatment strategies. The purpose of this review is to provide a comprehensive overview of asthma, encompassing its underlying mechanisms, the reasons for research underfunding, the impact of asthma on pediatric and adult populations, current treatment approaches, existing disparities in care and outcomes, and potential avenues for future research.

2. Pathophysiology of Asthma: A Complex Interplay of Factors

The pathophysiology of asthma is multifaceted, involving interactions between genetic predisposition, environmental exposures, and immunological responses [6]. At its core, asthma is characterized by chronic inflammation of the airways, leading to a cascade of events that contribute to airway hyperresponsiveness and airflow obstruction. The inflammatory process is driven by a variety of immune cells, including mast cells, eosinophils, T lymphocytes (Th2 cells, in particular), and innate immune cells [7]. These cells release a multitude of inflammatory mediators, such as histamine, leukotrienes, cytokines (IL-4, IL-5, IL-13), and chemokines, which contribute to airway edema, mucus hypersecretion, and bronchoconstriction [8].

2.1 Genetic Predisposition:

Genetic factors play a significant role in asthma susceptibility. Genome-wide association studies (GWAS) have identified numerous genetic variants associated with asthma risk, implicating genes involved in immune regulation, airway remodeling, and response to environmental stimuli [9]. For example, genes encoding subunits of the IL-13 receptor and major histocompatibility complex have been consistently linked to asthma susceptibility [10]. However, it is important to recognize that no single gene is responsible for asthma development; rather, asthma is a complex polygenic disorder resulting from the interaction of multiple genes with environmental factors. Furthermore, epigenetic modifications, such as DNA methylation and histone acetylation, can influence gene expression and contribute to asthma pathogenesis [11].

2.2 Environmental Exposures:

Environmental exposures play a crucial role in triggering and exacerbating asthma. Common environmental triggers include allergens (e.g., dust mites, pollen, pet dander), air pollutants (e.g., ozone, particulate matter), tobacco smoke, respiratory infections (e.g., rhinovirus), and occupational irritants [12]. Exposure to these triggers can lead to airway inflammation, bronchoconstriction, and increased mucus production. Early-life exposures, such as exposure to tobacco smoke or viral infections, can have a lasting impact on lung development and increase the risk of developing asthma later in life [13]. The hygiene hypothesis proposes that reduced exposure to microbes in early childhood can impair the development of a balanced immune system, leading to an increased susceptibility to allergic diseases, including asthma [14].

2.3 Immunological Mechanisms:

The immunological mechanisms underlying asthma are complex and involve both adaptive and innate immune responses. In allergic asthma, exposure to allergens triggers the activation of Th2 cells, which release cytokines such as IL-4, IL-5, and IL-13. IL-4 promotes IgE production by B cells, leading to sensitization to allergens. IL-5 activates eosinophils, which release cytotoxic mediators that contribute to airway inflammation and damage. IL-13 promotes mucus production and airway hyperresponsiveness [15]. In addition to Th2 cells, other immune cells, such as innate lymphoid cells (ILCs), play a role in asthma pathogenesis. ILC2s, in particular, are activated by epithelial-derived cytokines, such as IL-25 and IL-33, and release large amounts of IL-5 and IL-13, contributing to airway inflammation and hyperresponsiveness [16].

2.4 Airway Remodeling:

Chronic airway inflammation in asthma can lead to structural changes in the airways, a process known as airway remodeling. Airway remodeling is characterized by thickening of the airway wall due to subepithelial fibrosis, increased smooth muscle mass, increased mucus-secreting goblet cells, and angiogenesis [17]. These structural changes contribute to fixed airflow obstruction and reduced responsiveness to bronchodilators. Airway remodeling is thought to be driven by the release of growth factors and extracellular matrix proteins by inflammatory cells and structural cells in the airways [18]. While some degree of airway remodeling is reversible with treatment, persistent inflammation can lead to irreversible structural changes and chronic airflow limitation.

3. The Underfunding of Asthma Research: A Critical Issue

Despite its high prevalence and significant impact on global health, asthma research remains comparatively underfunded. This disparity in funding is particularly evident when compared to other chronic diseases with similar or lower prevalence rates, such as diabetes, cancer, and cardiovascular disease [19]. Several factors may contribute to this underfunding, including a lack of awareness of the severity of asthma, the perception that asthma is a “well-managed” disease, and the complex and heterogeneous nature of asthma, which makes it challenging to develop effective therapies.

One possible explanation for the underfunding of asthma research is that asthma is often viewed as a “childhood disease” that is “outgrown” in adulthood. While many children with asthma do experience remission of symptoms, a significant proportion continue to have asthma into adulthood, and some even develop asthma for the first time as adults [20]. Furthermore, even in children who experience remission, asthma can have long-term consequences, such as impaired lung function and increased risk of developing other respiratory diseases. Thus, the perception that asthma is a self-limiting childhood disease is inaccurate and contributes to the underestimation of its overall impact.

Another factor contributing to the underfunding of asthma research is the perception that asthma is a “well-managed” disease. While current therapies, such as inhaled corticosteroids and bronchodilators, can effectively control asthma symptoms in many patients, they do not address the underlying cause of the disease and are not effective for all patients [21]. Furthermore, long-term use of inhaled corticosteroids can have adverse effects, such as growth suppression in children and increased risk of osteoporosis in adults [22]. Thus, there is a clear need for more effective and safer therapies for asthma.

The complex and heterogeneous nature of asthma also contributes to the challenges in developing new therapies and securing research funding. Asthma is not a single disease entity, but rather a syndrome with multiple phenotypes and endotypes [23]. This heterogeneity makes it difficult to identify common therapeutic targets and develop therapies that are effective for all patients. Furthermore, clinical trials for asthma are often complicated by the variable nature of asthma symptoms and the difficulty in identifying appropriate endpoints. This complexity can increase the cost and risk of asthma research, making it less attractive to funders.

Addressing the underfunding of asthma research requires a multi-pronged approach, including increasing awareness of the severity and impact of asthma, advocating for increased research funding, and promoting collaboration between researchers, clinicians, and patient advocacy groups. It is also important to recognize that asthma is a complex and heterogeneous disease, and that a personalized approach to research and treatment is needed to achieve optimal outcomes. Improved funding models and collaborative research programs are necessary to facilitate the exploration of asthma’s complex mechanisms and the development of novel therapeutic strategies.

4. Impact of Asthma on Pediatric and Adult Populations

Asthma significantly impacts the health and well-being of both children and adults, affecting their physical, psychological, and social functioning. The burden of asthma extends beyond the individual, impacting families, schools, and healthcare systems.

4.1 Impact on Children:

Asthma is the most common chronic respiratory disease in children, affecting an estimated 8.4% of children in the United States [24]. Asthma is a leading cause of school absenteeism, emergency room visits, and hospitalizations in children [25]. Children with asthma often experience impaired quality of life, impacting their physical activity, sleep, and social participation. Furthermore, children with poorly controlled asthma may experience long-term consequences, such as impaired lung growth and development [26]. The psychological impact of asthma on children should not be underestimated. The chronic nature of the disease, the fear of exacerbations, and the limitations imposed on physical activity can lead to anxiety, depression, and low self-esteem [27].

4.2 Impact on Adults:

Asthma affects an estimated 7.9% of adults in the United States [28]. While asthma often begins in childhood, a significant proportion of adults develop asthma for the first time as adults. Adult-onset asthma is often more severe and less responsive to treatment than childhood-onset asthma [29]. Asthma is a leading cause of work absenteeism and reduced productivity in adults [30]. Adults with asthma may experience limitations in their physical activity, social participation, and overall quality of life. Severe asthma exacerbations can lead to hospitalization, intensive care, and even death. The economic burden of asthma in adults is substantial, resulting from healthcare utilization, medication costs, and lost productivity [31].

4.3 Impact on Healthcare Systems:

Asthma places a significant burden on healthcare systems worldwide. Asthma is a leading cause of emergency room visits, hospitalizations, and intensive care admissions [32]. The cost of asthma care includes medication costs, healthcare provider visits, diagnostic tests, and hospitalizations. Furthermore, asthma exacerbations often require urgent medical attention, placing a strain on emergency services and healthcare resources. Effective asthma management requires a comprehensive approach, including patient education, medication adherence, trigger avoidance, and regular monitoring of lung function. Integrated care models, such as asthma disease management programs, can improve asthma outcomes and reduce healthcare costs [33].

5. Current Treatment Approaches: Limitations and Challenges

The primary goals of asthma management are to control symptoms, prevent exacerbations, and improve quality of life. Current treatment approaches for asthma typically involve a combination of pharmacologic and non-pharmacologic interventions.

5.1 Pharmacologic Therapies:

The mainstay of asthma pharmacotherapy is inhaled corticosteroids (ICS), which reduce airway inflammation and prevent exacerbations. ICS are typically used as maintenance therapy for persistent asthma. Bronchodilators, such as short-acting beta-agonists (SABAs), are used to relieve acute asthma symptoms by relaxing airway smooth muscle. Long-acting beta-agonists (LABAs) are used in combination with ICS for long-term control of asthma symptoms. Leukotriene receptor antagonists (LTRAs) are oral medications that block the effects of leukotrienes, inflammatory mediators that contribute to airway inflammation and bronchoconstriction. Theophylline is a bronchodilator that is used less frequently due to its narrow therapeutic window and potential for side effects. Omalizumab is a monoclonal antibody that binds to IgE and prevents it from binding to mast cells, reducing allergic inflammation. Omalizumab is used for the treatment of severe allergic asthma. Biologic therapies that target specific inflammatory pathways, such as IL-5, IL-4Rα, and TSLP, have emerged as promising treatments for severe asthma [34].

5.2 Non-Pharmacologic Therapies:

Non-pharmacologic interventions play an important role in asthma management. Allergen avoidance is recommended for patients with allergic asthma. Smoking cessation is essential for patients who smoke. Regular exercise is encouraged to improve lung function and overall health. Patient education is crucial for promoting medication adherence, trigger avoidance, and self-management of asthma symptoms. Asthma action plans provide guidance on how to manage asthma symptoms and when to seek medical attention [35].

5.3 Limitations and Challenges:

Despite the availability of effective therapies, asthma remains poorly controlled in many patients. Medication non-adherence is a major challenge in asthma management. Many patients do not take their medications as prescribed, leading to uncontrolled symptoms and increased risk of exacerbations. The complexity of asthma regimens, the cost of medications, and the lack of patient education all contribute to medication non-adherence. Furthermore, current therapies do not address the underlying cause of asthma and are not effective for all patients. Some patients with severe asthma are refractory to conventional therapies and require high doses of corticosteroids or biologic therapies [36]. Long-term use of corticosteroids can have adverse effects, such as growth suppression in children and increased risk of osteoporosis in adults. There is a need for more effective and safer therapies that target the underlying mechanisms of asthma and are tailored to the individual patient’s needs.

6. Disparities in Asthma Care and Outcomes

Significant disparities exist in asthma care and outcomes across different populations, particularly based on race/ethnicity, socioeconomic status, and geographic location. These disparities highlight the need for targeted interventions to improve asthma outcomes in underserved communities.

6.1 Racial and Ethnic Disparities:

African American and Hispanic children have higher rates of asthma prevalence, hospitalizations, and mortality compared to white children [37]. These disparities are thought to be due to a complex interplay of factors, including environmental exposures, socioeconomic status, access to healthcare, and genetic predisposition. African American children are more likely to live in urban areas with high levels of air pollution and exposure to allergens [38]. They are also more likely to have lower socioeconomic status, which limits access to healthcare and resources for asthma management. Furthermore, genetic factors may contribute to the increased risk of asthma in African American and Hispanic populations [39].

6.2 Socioeconomic Disparities:

Children from low-income families have higher rates of asthma prevalence, hospitalizations, and mortality compared to children from higher-income families [40]. Low-income families often live in substandard housing with exposure to allergens and environmental irritants. They may also have limited access to healthcare and resources for asthma management. Furthermore, stress and food insecurity can exacerbate asthma symptoms in low-income populations [41].

6.3 Geographic Disparities:

Asthma prevalence and outcomes vary across geographic regions. Children living in urban areas and rural areas may face different challenges in accessing asthma care. Children in rural areas may have limited access to specialists and healthcare resources [42]. Children in urban areas may be exposed to high levels of air pollution and allergens. Addressing geographic disparities in asthma care requires tailored interventions to meet the specific needs of each community.

Addressing disparities in asthma care and outcomes requires a multi-pronged approach, including improving access to healthcare, addressing environmental exposures, promoting culturally sensitive asthma education, and advocating for policies that support asthma management in underserved communities. Community-based interventions, such as asthma home visiting programs, can be effective in improving asthma outcomes in low-income populations [43].

7. Future Research Directions: Toward Precision Medicine and Novel Therapies

Future research in asthma should focus on addressing the limitations of current therapies, understanding the complex pathophysiology of asthma, and developing more effective and personalized treatment strategies.

7.1 Precision Medicine Approaches:

Precision medicine, also known as personalized medicine, aims to tailor treatment to the individual patient based on their genetic, environmental, and clinical characteristics. In asthma, precision medicine approaches could involve identifying specific biomarkers that predict treatment response or disease progression [44]. These biomarkers could be used to select the most appropriate therapy for each patient and to monitor their response to treatment. For example, blood eosinophil levels can be used to predict response to anti-IL-5 therapies in patients with severe eosinophilic asthma [45]. Furthermore, advances in genomics and proteomics are enabling the identification of novel therapeutic targets for asthma. Single-cell RNA sequencing technologies provide unprecedented resolution for understanding cell-specific molecular mechanisms in the lung [46]. Understanding endotypes, or distinct subtypes of asthma based on underlying biological mechanisms, is crucial for developing targeted therapies. This approach requires deep phenotyping of patients to identify distinct biological pathways that drive disease in different individuals.

7.2 Novel Therapeutic Targets:

Identifying and validating novel therapeutic targets is crucial for developing more effective therapies for asthma. Several promising therapeutic targets are currently under investigation, including epithelial-derived cytokines (IL-25, IL-33, TSLP), innate immune cells (ILCs), and airway smooth muscle. Blocking epithelial-derived cytokines could reduce airway inflammation and hyperresponsiveness [47]. Targeting innate immune cells could prevent the initiation and amplification of allergic inflammation [48]. Inhibiting airway smooth muscle contraction could improve airflow obstruction [49]. The microbiome and its influence on immune development are also being actively investigated as a potential therapeutic target [50].

7.3 Strategies to Address Health Inequities:

Addressing health inequities in asthma care and outcomes requires targeted interventions to improve access to healthcare, address environmental exposures, promote culturally sensitive asthma education, and advocate for policies that support asthma management in underserved communities. Community-based interventions, such as asthma home visiting programs, can be effective in improving asthma outcomes in low-income populations. Furthermore, telemedicine and mobile health technologies can improve access to asthma care in rural and underserved areas [51].

7.4 New Technologies:

Advances in technology are revolutionizing asthma management. Wearable sensors can track asthma symptoms and environmental exposures, providing real-time feedback to patients and healthcare providers [52]. Smart inhalers can monitor medication adherence and provide reminders to patients. Artificial intelligence and machine learning can be used to predict asthma exacerbations and personalize treatment [53]. These technologies have the potential to improve asthma outcomes and reduce healthcare costs.

8. Conclusion

Asthma remains a significant global health burden, affecting millions of children and adults worldwide. Despite the availability of effective therapies, asthma remains poorly controlled in many patients, and significant disparities exist in asthma care and outcomes. The underfunding of asthma research hinders progress in understanding the complex pathophysiology of asthma and developing more effective and personalized treatment strategies. Future research should focus on precision medicine approaches, novel therapeutic targets, strategies to address health inequities, and the use of new technologies to improve asthma management. Increased investment in asthma research is essential to accelerate progress toward more effective and equitable asthma care.

References

[1] Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2023. Available from: www.ginasthma.org.
[2] Asher, M. I., et al. “Worldwide trends in the prevalence of asthma symptoms and asthma medication use in childhood: ISAAC Phase One and Three repeat multicountry cross-sectional surveys.” The Lancet 368.9537 (2006): 733-743.
[3] Masoli, M., et al. “The global burden of asthma: executive summary of the GINA Dissemination Committee report.” Allergy 59.5 (2004): 469-478.
[4] Pearce, N., et al. “Worldwide trends in asthma symptoms in children: the ISAAC Phase Three study.” Thorax 62.9 (2007): 758-766.
[5] Juniper, E. F., et al. “Development and validation of the mini asthma quality of life questionnaire.” European Respiratory Journal 14.1 (1999): 32-38.
[6] Holgate, S. T. “Pathogenesis of asthma.” Clinical & Experimental Allergy 38.6 (2008): 872-887.
[7] Lambrecht, B. N., and H. Hammad. “The immunology of asthma.” Nature Immunology 16.1 (2015): 45-56.
[8] Kumar, R. K., et al. “Inflammatory mechanisms in asthma.” Immunologic Research 64.5-6 (2016): 1120-1135.
[9] Moffatt, M. F., et al. “A large-scale, genome-wide association study of asthma identifies new risk loci.” Nature Genetics 42.3 (2010): 224-229.
[10] Torgerson, D. G., et al. “Meta-analysis of genome-wide association studies of asthma in European-ancestry populations.” Nature Genetics 43.9 (2011): 887-892.
[11] Vercelli, D. “Discovering susceptibility genes for asthma and allergy.” Nature Reviews Immunology 8.12 (2008): 911-922.
[12] Bousquet, J., et al. “Environmental factors associated with asthma: a systematic review.” Allergy 62.5 (2007): 469-482.
[13] Strickland, M. J., et al. “Early life exposure to environmental tobacco smoke and asthma incidence.” American Journal of Respiratory and Critical Care Medicine 176.11 (2007): 1071-1076.
[14] Strachan, D. P. “Hay fever, hygiene, and household size.” BMJ 299.6710 (1989): 1259-1260.
[15] Wills-Karp, M. “The immunologic basis of allergic asthma: from allergens to T lymphocytes.” Advances in Immunology 92 (2006): 1-25.
[16] Walker, J. A., et al. “Innate lymphoid cells– emerging roles in allergic inflammation.” Clinical & Experimental Allergy 43.9 (2013): 987-997.
[17] James, A. L., and P. W. Noble. “Airway remodelling in asthma.” Current Opinion in Pulmonary Medicine 11.1 (2005): 1-5.
[18] Mauad, T., et al. “Airway remodeling in asthma.” American Journal of Respiratory and Critical Care Medicine 175.9 (2007): 983-988.
[19] National Institutes of Health (NIH). Research, Condition, and Disease Categorization (RCDC). Accessed November 4, 2023. https://report.nih.gov/.
[20] Sly, P. D., et al. “Factors influencing the persistence of asthma from childhood to adulthood.” Journal of Allergy and Clinical Immunology 118.3 (2006): 653-660.
[21] Bateman, E. D., et al. “GINA guideline 2021 main report.” Global Initiative for Asthma (2021).
[22] Kelly, H. W., and R. G. Nielson. “Systemic glucocorticoid effects during inhaled corticosteroid use.” Annals of Pharmacotherapy 32.11 (1998): 1127-1134.
[23] Wenzel, S. E. “Asthma phenotypes: the evolution from clinical to molecular approaches.” Nature Medicine 18.5 (2012): 716-725.
[24] Centers for Disease Control and Prevention (CDC). Asthma in Children. Accessed November 4, 2023. https://www.cdc.gov/asthma/children.htm.
[25] Akinbami, L. J., et al. “Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010.” NCHS data brief, no 94 (2012).
[26] Lange, P., et al. “Effect of asthma and inhaled corticosteroids on growth in children.” The New England Journal of Medicine 374.19 (2016): 1817-1826.
[27] McQuaid, E. L., and P. J. Walders. “Psychological aspects of childhood asthma.” Clinical Psychology Review 21.6 (2001): 829-858.
[28] Centers for Disease Control and Prevention (CDC). Asthma in Adults. Accessed November 4, 2023. https://www.cdc.gov/asthma/adult_asthma.htm.
[29] Moore, W. C., et al. “Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program.” American Journal of Respiratory and Critical Care Medicine 181.4 (2010): 315-323.
[30] Burton, W. N., et al. “The economic burden of asthma in the United States, 2002-2007.” Journal of Occupational and Environmental Medicine 54.1 (2012): 1-7.
[31] Nurmagambetov, T., et al. “The economic burden of asthma in the United States, 2008-2013.” Annals of the American Thoracic Society 15.5 (2018): 574-581.
[32] Weiss, K. B., et al. “Self-reported asthma morbidity in US adults with current asthma.” The Journal of Allergy and Clinical Immunology 105.5 (2000): 922-929.
[33] Clark, N. M., et al. “Self-management of asthma.” The American Journal of Respiratory and Critical Care Medicine 157.5 Pt 2 (1998): S1-S10.
[34] Castro, M., et al. “Tralokinumab for moderate-to-severe asthma: a placebo-controlled, phase 2, dose-ranging study.” The Lancet Respiratory Medicine 6.2 (2018): 127-136.
[35] National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007.
[36] Chung, K. F., et al. “International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.” European Respiratory Journal 43.2 (2014): 343-373.
[37] Centers for Disease Control and Prevention (CDC). Asthma Disparities. Accessed November 4, 2023. https://www.cdc.gov/asthma/disparities.htm.
[38] Clougherty, J. E., et al. “Socioeconomic disparities in air pollution and health: an overview.” Environmental Health Perspectives 114.7 (2006): 1073-1080.
[39] Burchard, E. G., et al. “The importance of race and ethnic background in respiratory genetics research.” Proceedings of the American Thoracic Society 1.3 (2004): 221-228.
[40] Chen, E., and G. S. Miller. “Associations between socioeconomic status and asthma prevalence and morbidity in US children.” Chest 120.1 (2001): 70-79.
[41] Adamkiewicz, G., et al. “Housing conditions and risk of asthma exacerbations in children in public housing.” American Journal of Public Health 101.12 (2011): 2285-2292.
[42] Bennett, K. J., et al. “Rural-urban differences in childhood asthma prevalence and morbidity in the United States.” The Journal of Rural Health 20.1 (2004): 71-78.
[43] Crocker, D. D., et al. “Effectiveness of home-based asthma interventions on asthma outcomes: a systematic review and meta-analysis.” American Journal of Preventive Medicine 40.1 (2011): 1-11.
[44] Woodruff, P. G., et al. “Integrative biomarkers identify distinct subtypes of asthma with differential responses to inhaled corticosteroids.” PLoS One 6.6 (2011): e20082.
[45] Pavord, I. D., et al. “Rationale and design of the phase 3 clinical development programme for benralizumab, a monoclonal antibody to interleukin-5 receptor alpha, in severe, uncontrolled eosinophilic asthma.” European Respiratory Journal 48.4 (2016): 998-1009.
[46] Ordovas-Montanes, J., Dwyer, D.F., Nyquist, S.K. et al. Allergic inflammatory memory in human respiratory epithelial progenitor cells. Nature 588, 674–679 (2020).
[47] Locksley, R. M. “IL-25 and IL-33: Master regulators of type 2 immunity.” Immunological Reviews 242.1 (2011): 8-20.
[48] Artis, D., and A. M. Spits. “The biology of innate lymphoid cells.” Nature 517.7534 (2015): 339-348.
[49] Gosens, R., and J. D. Nelemans. “Airway smooth muscle as a target for asthma therapy.” Trends in Pharmacological Sciences 32.4 (2011): 230-237.
[50] Arrieta, M. C., et al. “Early infancy microbial and metabolic alterations affect risk of childhood asthma.” Science Translational Medicine 7.307 (2015): 307ra152.
[51] Doshi, A., et al. “Impact of telemedicine on asthma outcomes: a systematic review.” Allergy and Asthma Proceedings 38.5 (2017): 338-347.
[52] Ali, Z., et al. “Wearable sensors for asthma monitoring: a review.” Sensors 16.5 (2016): 734.
[53] Ben-Yehuda Greenblatt, O., et al. “Artificial intelligence in asthma: a review of current applications and future directions.” Journal of Allergy and Clinical Immunology: In Practice 6.1 (2018): 1-12.